Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

106 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Tumor-intrinsic oncogene pathways mediating immune avoidance.
Spranger S, Gajewski TF. Spranger S, et al. Oncoimmunology. 2015 Aug 31;5(3):e1086862. doi: 10.1080/2162402X.2015.1086862. eCollection 2016 Mar. Oncoimmunology. 2015. PMID: 27141343 Free PMC article. Review.
Tissue Site and the Cancer Immunity Cycle.
Horton BL, Fessenden TB, Spranger S. Horton BL, et al. Among authors: spranger s. Trends Cancer. 2019 Oct;5(10):593-603. doi: 10.1016/j.trecan.2019.07.006. Epub 2019 Aug 13. Trends Cancer. 2019. PMID: 31706507 Free PMC article. Review.
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment.
Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, Spranger S. Gajewski TF, et al. Among authors: spranger s. Curr Opin Immunol. 2013 Apr;25(2):268-76. doi: 10.1016/j.coi.2013.02.009. Epub 2013 Apr 8. Curr Opin Immunol. 2013. PMID: 23579075 Review.
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.
Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Spranger S, et al. Sci Transl Med. 2013 Aug 28;5(200):200ra116. doi: 10.1126/scitranslmed.3006504. Sci Transl Med. 2013. PMID: 23986400 Free PMC article.
Rational combinations of immunotherapeutics that target discrete pathways.
Spranger S, Gajewski T. Spranger S, et al. J Immunother Cancer. 2013 Sep 23;1:16. doi: 10.1186/2051-1426-1-16. eCollection 2013. J Immunother Cancer. 2013. PMID: 24829752 Free PMC article. Review.
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.
Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Spranger S, et al. J Immunother Cancer. 2014 Feb 18;2:3. doi: 10.1186/2051-1426-2-3. eCollection 2014. J Immunother Cancer. 2014. PMID: 24829760 Free PMC article.
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, Duggan R, Wang Y, Barber GN, Fitzgerald KA, Alegre ML, Gajewski TF. Woo SR, et al. Among authors: spranger s. Immunity. 2014 Nov 20;41(5):830-42. doi: 10.1016/j.immuni.2014.10.017. Epub 2014 Nov 5. Immunity. 2014. PMID: 25517615 Free PMC article.
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.
Spranger S, Bao R, Gajewski TF. Spranger S, et al. Nature. 2015 Jul 9;523(7559):231-5. doi: 10.1038/nature14404. Epub 2015 May 11. Nature. 2015. PMID: 25970248
A new paradigm for tumor immune escape: β-catenin-driven immune exclusion.
Spranger S, Gajewski TF. Spranger S, et al. J Immunother Cancer. 2015 Sep 15;3:43. doi: 10.1186/s40425-015-0089-6. eCollection 2015. J Immunother Cancer. 2015. PMID: 26380088 Free PMC article.
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
Zhai L, Spranger S, Binder DC, Gritsina G, Lauing KL, Giles FJ, Wainwright DA. Zhai L, et al. Among authors: spranger s. Clin Cancer Res. 2015 Dec 15;21(24):5427-33. doi: 10.1158/1078-0432.CCR-15-0420. Epub 2015 Oct 30. Clin Cancer Res. 2015. PMID: 26519060 Free PMC article. Review.
106 results
Jump to page